Grace Therapeutics

GRCENasdaq Canada Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$45.017 M

$2.14 +1.91%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$7.79M

Loss-making

Shares outstanding

16,274,026

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#357ScynexisSCYX$48.4M
#358Werewolf TherapeuticsHOWL$47.7M
#359Grace TherapeuticsGRCE$45.0M
#360VeruVERU$42.6M
#361Nasus PharmaNSRX$41.8M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Grace Therapeutics, worth $24.2K. Grants and option exercises are excluded.

Opaleye Management Inc.$24.2K
11,608 shares at $2.09 on 14 Aug 2026 · filed 19 Aug 2026

What if Grace Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$1,437,254

Per share 671,614× higher

Bitcoin $1.74T

$82,794.30

Per share 38,689× higher

Nvidia $5.52T

$262,206.95

Per share 122,527× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Grace Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.